[Superficial angiomas: Treatment].

Area of Science:

• Vascular biology and medicine
• Medical imaging
• Pharmacology

Background:

• Infantile hemangiomas are common benign tumors treated with beta-blockers, notably propranolol.
• Superficial vascular malformations require a multidisciplinary approach for optimal management.
• Arteriovenous malformations represent aggressive lesions with limited therapeutic strategies.

Purpose of the Study:

• To review current and emerging treatments for infantile hemangiomas and vascular malformations.
• To highlight the role of advanced imaging in diagnosing vascular malformations.
• To explore novel therapeutic targets in the molecular biology of vascular anomalies.

Main Methods:

• Review of current literature on infantile hemangiomas and vascular malformations.
• Discussion of the utility of T2 FAT-SAT MRI in evaluating superficial vascular malformations.
• Exploration of genetic mutations and molecular targets, including mTOR inhibitors.

Main Results:

• Propranolol is the established first-line treatment for complicated infantile hemangiomas.
• T2 FAT-SAT MRI is identified as a key imaging sequence for superficial vascular malformations.
• Mammalian target of rapamycin (mTOR) inhibitors show promise for treating slow-flow malformations.

Conclusions:

• Beta-blockers remain crucial for infantile hemangiomas.
• Multidisciplinary care and advanced imaging like T2 FAT-SAT MRI are essential for vascular malformations.
• Targeting genetic mutations and utilizing mTOR inhibitors represent promising future therapeutic avenues for complex vascular lesions.